Treatment cycle | Effect of treatment on signs and symptoms | Adverse events |
---|---|---|
Pre-treatment | Pain 9/10* Facial mass 89 mm | N/A |
1 | Pain reduction to 2/10* after 7 days, with discontinuation of oral morphine after 4 days Reduction of facial mass to 70 mm | Grade 2 nausea |
2 | Labial and periorbital facial oedema reduced Reduction of facial mass to 40 mm | Grade 2 nausea Grade 2 neutropenia Next treatment cycle delayed by one week |
3 | Pain resolved (0/10)* and pain relief discontinued Facial oedema resolved CT scan: partial tumour remission, with marked reduction of retromandibular mass | Grade 2 anaemia |
4 | No pain relief requirement | Grade 2 anorexia Grade 2 vomiting Grade 2 asthenia Grade 2 mucositis Grade 3 anaemia (requiring red cell transfusion) Grade 1 acne-like rash (facial) |
Cetuximab maintenance (7 continuous months of treatment) | No pain relief requirement | Grade 2 mucositis Grade 2 acne-like rash (painful lesions on the scalp) Cetuximab discontinued for 3 weeks |